[Clinicofunctional condition and quality of life in patients with chronic obstructive pulmonary disease before and after outpatient treatment with fenspiride].
OBJECTIVE
To study effects of long-term administration of fenspiride in combination with broncholytic drugs on dynamics of clinical symptoms, external respiration function and quality of life in patients with chronic obstructive pulmonary disease (COPD).


METHODS
A comparative randomized trial of fenspiride used for 6 months in combination with broncholytic drugs enrolled 68 COPD patients. A clinical status, external respiration function were examined. Quality of life was evaluated with WHO questionnaire WHOQOL-100.


RESULTS
Addition of fenspiride to combined treatment of COPD attenuates COPD symptoms, normalizes blood biochemistry, improves external respiration function, raises exercise tolerance. Quality of life improved by physical and mental state scales.


CONCLUSIONS
Fenspiride addition to COPD treatment improves efficacy of the standard treatment and is recommended for treatment of COPD of stage I and II in combination with broncholytic drugs.
Butorov
S I
SI
Butorov
I V
IV
Bodrug
N I
NI
Krushka
S I
SI
Tofan
E F
EF
D000328:Adult; D000553:Ambulatory Care / Q000379:methods*; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D017079:Exercise Tolerance / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D011788:Quality of Life; D013141:Spiro Compounds / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014797:Vital Capacity / Q000502:physiology*
D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D013141:Spiro Compounds; C084775:fenspiride